Skip to main content

Table 1 Baseline characteristics of patients

From: Postoperative XELOX therapy for patients with curatively resected high-risk stage II and stage III rectal cancer without preoperative chemoradiation: a prospective, multicenter, open-label, single-arm phase II study

 

n = 107

Age, years (range)

63 (29–77)

Sex

 Male

60 (56%)

 Female

47 (44%)

Eastern Clinical Oncology Group (ECOG) paformance status

 0

93 (87%)

 1

14 (13%)

Main location of the tumor

 Rectosigmoid

5 (5%)

 Upper rectum

54 (50%)

 Lower rectum

48 (45%)

Surgical approach

 Laparoscopic

77 (72%)

 Open

30 (28%)

Surgical procedure

 HAR

10 (9%)

 LAR

79 (74%)

 ISR

4 (4%)

 Hartmann’s procedure

2 (2%)

 APR

12 (11%)

 Lateral lymph node dissection by the main location of the tumor

19 (18%)

 Upper rectum

3

 Lower rectum

16

 Operation time, minutes (range)

311 (122–914)

 Intraopelative bleeding, ml (range)

45 (0–2100)

 Stoma creation

47 (44%)

 Postoperative complications

18 (17%)

Histology

 pap/tub1/tub2

1/33/71

 por1/por2/muc/sig

1/1/0/0

Pathological T category

 T1

7 (7%)

 T2

19 (18%)

 T3

66 (62%)

 T4a

12 (11%)

 T4b

3 (3%)

Pathological N category

 N0

8 (8%)

 N1a

24 (22%)

 N1b

29 (27%)

 N2a

21 (20%)

 N2b

25 (23%)

Pathological stage

 IIA

5 (5%)

 IIB

3 (3%)

 IIIA

17 (16%)

 IIIB

57 (53%)

 IIIC

25 (23%)

  1. HAR high anterior resection, LAR low anterior resection, ISR intersphincteric resection, APR abdominoperineal resection